Don’t Wait - Recommend Florastor^®During and After Antibiotic Therapy

Florastor^®significantly reduces the risk of of antibiotic-associated diarrhea¹

The incidence of diarrhea in adult patients receiving Florastor (S. boulardii CNCM I-745®) was significantly lower (N=1/73, 1.4%) vs. placebo (n=7/78, 9%; p<0.05).

• DURING antibiotic therapy, Florastor significantly slows the decline of healthy gut flora*²

• AFTER antibiotic therapy, Florastor speeds up the restoration of healthy gut flora to restore the patient's well-being*²

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Florastor^® Safety Warning
Do not use Florastor or other probiotics in any ICU setting and in those individuals with open arterial and venous access required (such as a Vascath, Permcath, or AV fistula). Do not use for any individual with a central line or port or in the surroundings of any patient with a central line or port. [Central lines include short- and long-term central venous catheters (CVCs) and peripherally inserted central catheters (PICCs)]. Do not use Florastor for pre- or post- organ or bone marrow transplant patients and other patients considered severely immunocompromised or critically ill. Do not use Florastor probiotics if allergic to any components (especially yeast). Very rarely, side effects such as: allergic reaction (skin rash). Fungemia or sepsis in patients with a central venous catheter, and in hospitalized, immunocompromised patients may occur.

For product questions or to report an adverse event, please call 877-356-7787.

References:
1. Can M et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Medical Science Monitor. 2006;12(4):2004-2007.
2. More MI, Swidsinski A. Saccharomyces boulardii CNCM I-745® supports regeneration of the intestinal microbiota after diarrheic dysbiosis – A review. Clinical and Experimental Gastroenterology. 2015;8:237-255. doi:10.2147/CEG.S85574.